 |
|
Surveillance for hepatocellular carcinoma: It is time to move forward
Bo Hyun Kim, Yuri Cho, Joong-Won Park
Clin Mol Hepatol. 2022;28(4):810-813. Published online 2022 Sep 6 DOI: https://doi.org/10.3350/cmh.2022.0257
|
|
Citations to this article as recorded by
 Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
Won Sohn, Yong-Han Paik
Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
Shen-Yung Wang
Clinical and Molecular Hepatology.2023; 29(2): 349. CrossRef What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef
|